Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATAR - Multimedia Available: Atari Ships New Backyard Baseball PS2 Game Starring New
York Yankee Alex Rodriguez
Entertainment Editors
ADVISORY...for Monday (April 5)
NOTE TO EDITORS: Multimedia Assets Available With This Story
Include Logos, Photos, Text News Releases
--(BUSINESS WIRE)--
Batter up! Atari Inc. (Nasdaq:ATAR) and Major League Baseball(R)
(MLB(R)) have announced that Backyard Baseball(tm) for the
PlayStation(R)2 computer entertainment system has shipped to retail
stores nationwide. Starring Alex Rodriguez, the New York Yankees(tm)
newly acquired third baseman, Backyard Baseball(tm) is the newest game
in the award-winning Backyard Sports(tm) franchise -- the only sports
series that let kids play with their favorite pro players as kid sized
versions of themselves.
You can reach the story directly by going to
http://www.newstream.com/cgi-bin/display_story.cgi?12977
This multimedia news story is for free and unrestricted use on
your news information site (and for print or broadcast too). Visit
http://www.newstream.com to download video, audio, text, graphics, and
photos.
If you have any questions about the story, or about Newstream.com,
please write to us at info@newstream.com.
--30--CSD/sa*
CONTACT: Newstream.com, New York
info@newstream.com
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: SPORTS ENTERTAINMENT ELECTRONIC GAMES/MULTIMEDIA
ADVISORY PRODUCT
SOURCE: Newstream and Atari Inc.
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Apr-05-2004 12:23 GMT
Symbols:
US;ATAR
Source BW Business Wire
Categories:
MST/I/CSE MST/I/ENT MST/I/HES MST/I/RCS MST/L/EN MST/R/US/MA
MST/S/PDT TGT/BWN
LOL yes! I have Fidelity Active Trader Pro though for streaming charts, and they actually cleared the bad price out within about 15 minutes. Not exactly on topic, but I was waiting for an exit point to complete an option roll-up on QQQ. It's all set and I'm calmer now.
:-P
doncha just hate that?
OT
arrrrggggghhhh!!!!!! I cant stand when these $*&&%$#@&&% pinheads ruin a chart with a bad price... My QQQ chart is trashed... TRASHED! GRRRRR... I have no clue where the trendline is at this point...
hehehe...That was one of the first things Walter Williams talked about on the radio today.
ok, here's the Demo spinjob...
Hoyer: Employment Report Is Welcome News But Provides Little Vindication for Bush Policies
/FROM PR NEWSWIRE WASHINGTON DC 202-347-5155/
TO NATIONAL AND POLITICAL EDITORS:
Hoyer: Employment Report Is Welcome News
But Provides Little Vindication for Bush Policies
Unemployment Rate in March Actually Inches Up,
With 200,000 More Unemployed
WASHINGTON, April 2 /PRNewswire/ -- House Democratic Whip Steny H. Hoyer
(MD) released the following statement this morning regarding the Department of
Labor's employment report for March, which showed that 308,000 jobs were
created last month:
"The Labor Department's report today is long-overdue welcome news for job
seekers, but one month does not a successful economic policy make. Even if
the economy added this number of jobs every month for the rest of the year,
George W. Bush would barely break even on job creation for his entire four-
year term and have the worst record of job creation since the Great
Depression.
"While the Bush Administration will undoubtedly pop open the champagne
bottles today, the plight of the over 8 million unemployed Americans demands
some perspective.
"First, the unemployment rate in March actually increased to 5.7 percent
and the number of unemployed Americans rose to 8.4 million because 200,000 job
seekers re-entered the job market.
"And second, a simple comparison with the Clinton Administration
demonstrates the current Administration's continued abysmal economic
performance. Over its eight years, the Clinton Administration presided over
an economy that created 22 million jobs in eight years, an average job gain of
229,000 every single month. During the last three and one-half years, the
economy has lost more than 2 million jobs.
"While I hope that we will see continued job gains in the coming months,
the Bush Administration should not celebrate too loudly in the face of an
increased unemployment rate."
CONTACT: Stacey Farnen of the Office of the Democratic Whip,
+1-202-225-3130.
SOURCE Office of the Democratic Whip
/CONTACT: Stacey Farnen of the Office of the Democratic Whip,
+1-202-225-3130/
/Web site: http://www.democraticwhip.house.gov/
OT (politics; feel free to delete this post if you want, Art)
lmao, agreed! I'll have to listen to Rush's program today. Walter Williams is going to be subbing and he's a very laissez-faire guy such as myself. I like listening to him better than Rush. He'll probably be gloating all day!
:-P
Wow, this was triple the expectations, how were they off so much? also the Sharp upward revisions for Jan and Feb...?
Will be interesting to hear the DEMs spin machine out there today...rotf!
Jobs Report: UP 308,000!!!!! January and February numbers revised drastically upwards as well.
Futures pits are going nuts; NAZ futures up 19 last time I looked.
Hope no one's short today...
BIOM - Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial in Non-Small Cell Lung Cancer Shows Evidence of a 4.4 Month Overall Improvement in Survival
/FROM CANADA NEWSWIRE CALGARY 403-269-7605/
TO BUSINESS EDITOR:
Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial
in Non-Small Cell Lung Cancer Shows Evidence of a 4.4 Month Overall
Improvement in Survival
EDMONTON, AB and DARMSTADT, GERMANY, April 2 /PRNewswire-FirstCall/ -
Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) and Merck KGaA of Darmstadt, Germany,
said today preliminary results from a randomized, open-label Phase IIb trial
of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non-
small cell lung cancer (NSCLC) indicate that the median survival of those
patients on the vaccine arm was 4.4 months longer than those on the control
arm. Although not statistically significant, the overall median survival is
17.4 months for patients on the vaccine arm versus 13 months for the patients
on the control arm.
Importantly, the observed two-year survival for patients with
locoregional Stage IIIb disease is 60 per cent for the vaccine arm (median
survival not yet reached) versus 36.7 per cent for the control arm (median
survival of 13.3 months). In the overall patient population the two-year
survival is 43.2 per cent for the vaccine arm versus 28.9 per cent for the
control arm.
"Our overall survival analysis, is, in our opinion, clinically
compelling," said Alex McPherson, MD, PhD, President and CEO of Biomira. "We
are very encouraged by these results and are developing plans for further
clinical testing of L-BLP25 in lung cancer and possibly other indications.
Although not finalized, our plans will likely include a multinational Phase
III registration trial."
The controlled, open-label Phase IIb trial enrolled 171 men and women
with NSCLC whose disease was stable or who had responded to treatment
following completion of their first line standard chemotherapy. Patients were
randomized to either L-BLP25 plus best standard of care or to best standard of
care alone. Best standard of care includes palliative radiotherapy and/or
second line chemotherapy according to current standard clinical practice. The
study was designed to document the safety profile of the vaccine and to
evaluate efficacy by comparing survival in the two arms.
The results appear to indicate a favourable safety profile. Additional
analyses and survival follow-up will be conducted to gather information to
assist in the future development of the product.
"Lung cancer is a very aggressive disease and the observation of a 4.4
month improvement in median survival for patients treated with L-BLP25 in this
well-controlled trial is a clinically important finding for this serious
illness," said Nancy Wysenski, president of EMD Pharmaceuticals, Inc., the U.S
subsidiary of Merck KGaA. "We appreciate the participation of the patients and
investigators in this study that has yielded this important finding."
Dr. Frances Shepherd, Chairman of the Data Safety Monitoring Board (DSMB)
for the Phase IIb trial complimented the Companies saying, "This study was
conducted in an exemplary fashion and the high quality data resulting from the
trial can now be used in planning the next phase of clinical development."
In preparation for the potential multinational registration trial,
Biomira is already scheduling for the manufacture of new vaccine supplies.
This will incorporate manufacturing changes intended to secure the future
commercial supply of the vaccine. Scheduling these changes now ensures that
the resulting pivotal data will be considered representative of the safety and
effectiveness of the commercial supply of the vaccine. To assure the
successful initiation of a pivotal trial, a comparability plan, which may or
may not include clinical data, will be discussed with regulatory authorities.
L-BLP25 vaccine
L-BLP25 is a synthetic MUC1 peptide vaccine. L-BLP25 incorporates a
25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal
delivery system. The liposome enhances recognition of the cancer antigen by
the immune system and facilitates better delivery. L-BLP25 is designed to
induce an immune response to cancer cells.
About Lung Cancer
Lung cancer is the leading cause of cancer-related mortality for both
sexes in North America. In 2004, approximately 174,000 new cases of lung
cancer will be diagnosed in the U.S. - 54 per cent of them in men and 46 per
cent in women. Approximately 160,000 people will die of this disease in the
U.S. alone in 2004. In Canada, the mortality percentages are slightly higher
for men - 57 per cent of deaths from lung cancer will occur in men and 43 per
cent will be in women. NSCLC accounts for approximately 75 to 80 per cent of
all primary lung cancers. At the time of diagnosis, only 25 per cent of
patients are potentially curable by surgery.
L-BLP25 Prostate Study
In addition to the Phase IIb trial for men and women with Stage IIIb and
IV NSCLC, in 2002 Biomira also completed enrolment in a second pilot study
with L-BLP25 in patients with prostate cancer. A 16-patient L-BLP25 Phase II
pilot study in patients with rising prostate specific antigen (PSA) post
radical prostatectomy was conducted to determine whether the vaccine could
reduce or stabilize PSA levels. L-BLP25 showed a good safety profile, and the
dose and schedule were also well accepted by the patients. Preliminary results
in this small patient population did not conclusively show a reduction or
stabilization of serum PSA levels. However, there appears to be a prolongation
of PSA doubling time (PSADT) in just under 40 per cent of the patients. While
there has been no commitment to conduct further trials at this time in this
indication, the patients continue to be followed for PSA levels for a period
of 12 months following their last vaccination.
Theratope(R) Vaccine
Biomira and Merck KGaA are also collaborating on the development of
Theratope vaccine in the treatment of metastatic breast cancer. The Companies
are continuing subset analyses in one pre-stratified subset of more than 300
women who received hormonal treatment following chemotherapy in a Phase III
study. In the subset, those women who received Theratope appeared to show a
favourable trend toward improvement in survival. A Phase II study of Theratope
in metastatic breast cancer is also enrolling patients in the U.S. Women in
this trial have a less aggressive disease than those in the Phase III trial,
and full enrolment is expected in the first half of 2004. The Companies expect
to announce their corporate strategy for Theratope by the end of the second
quarter of 2004.
The Companies
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy. We are The Cancer
Vaccine People(TM).
With more than 34,200 employees in 53 countries, the Merck Group
generated sales of EUR 7.2 billion in 2003. Founded in 1668 in Darmstadt,
Germany, the Company aims to be a world leader in its core businesses of
pharmaceuticals and chemicals. Merck groups its operating activities under
Merck KGaA, in which the Merck family holds 74 percent and the remaining 26
percent is publicly traded. The former U.S. subsidiary, Merck & Co., has been
a completely independent company since 1917. Merck KGaA has built a strategic
oncology portfolio by developing and in-licensing product candidates in four
areas -- monoclonal antibodies, therapeutic vaccines, immunocytokines and
angiogenesis inhibitors.
EMD Pharmaceuticals Inc., the U.S. affiliate of Merck KGaA, is a fully
integrated pharmaceutical company with an initial emphasis on launching new
products in oncology. Located in Durham, N.C., EMD focuses on meeting patient
and physician needs with pioneering pharmaceutical products and services.
Conference Call Details:
Today at 10:30 a.m. EDT, Biomira Inc. and Merck KGaA will webcast an
analyst conference call hosted by Alex McPherson, MD, PhD, President and CEO
of Biomira. Investors and the general public are invited to listen to the live
conference call on the Web, by accessing the following site:
http://viavid.net/dce.aspx?sid(equal sign)00001AB2 or the archive following
the call at www.biomira.com. The archive of the analyst conference call will
be available on the Biomira Web site for approximately 30 days following the
live call. Analysts may participate in the conference call at 1-800-651-8979
(North America toll-free) or 1-706-634-5011, 0-800-91-742-60(United Kingdom),
0-800-181-5287 (Germany), approximately 10 minutes before the start of the
call.
Except for historical information contained herein, this release contains
forward-looking statements that are subject to risks and uncertainties that
may cause actual results to differ materially from the results discussed in
the forward-looking statements, particularly those risks and uncertainties
surrounding the efficacy of L-BLP25 vaccine to treat men and women with NSCLC,
which may include risks and uncertainties inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics. Factors that may cause such a difference
include the risk that further analyses of the data from our clinical trials
may not support the results observed to date, the risk that additional trials
may not demonstrate the safety and efficacy required to satisfy the regulatory
authorities, the risk that the Company may lack the financial resources and
access to capital to fund the required clinical trials, or that it will elect
to conduct such additional trials, and other matters required to bring
products to market, the uncertainties as to when, if at all, the regulatory
authorities will agree to discuss the trial results with the Company and
whether they will approve the product and manufacturing facilities, the need
to establish and scale-up manufacturing processes, dependence on the efforts
of third parties, including suppliers and collaborators, dependence on
intellectual property rights and the effectiveness thereof, difficulties or
delays in manufacturing products, and regulatory developments involving
products and manufacturing facilities. For more detailed information on the
risks and uncertainties associated with the Company's product candidates and
other activities see the Company's periodic reports filed with the applicable
securities regulatory authorities in Canada and the United States Securities
and Exchange Commission. The Company assumes no obligation to update any
forward-looking statements.
SOURCE Biomira Inc.
/CONTACT: Biomira Company Contacts: Bill Wickson, Manager, Public
Relations, 780-490-2818, After hours contact: bwickson@biomira.com ,
JaneTulloch, Director, Investor Relations, 780-490-2812, Merck KGaA
Contacts:Juergen Knackmuss, Spokesperson, 011-49-6151-72-2386, EMD
PharmaceuticalsMedia Contact: David Reeder, Director, Corporate Communications,
919-401-7200;To request a free copy of this organization's annual report, please
go tohttp://www.newswire.ca and click on reports@cnw./
Apr-02-2004 12:30 GMT
Symbols:
CA;BRA US;BIOM
Source PRN PR Newswire
Categories:
NWI/BIO NWI/HEA NWI/MTC NWI/SPM NWR/AB MST/I/BTC MST/I/DRG MST/I/HCS
MST/I/HEA MST/L/EN MST/MST/I/BTC MST/MST/I/DRG MST/MST/I/HEA MST/MST/L/EN
MST/MST/R/CA MST/R/CA TGT/PRN
ALAN - the avg volume is a bit low, but it does seem to be picking up lately
Art does ALAN fit the bill?
Average Volume (3 month): 209,227
Market Cap (intraday): 17.41M
Last Trade: 0.94
U.S. stocks set to open flat, inflation data tame
NEW YORK, April 1 (Reuters) - U.S. stocks are set to open
near unchanged or slightly higher on Thursday as investors
welcome positive jobs and inflation data.
The government said 342,000 Americans made their first
claims for unemployment benefits last week, down from a revised
345,000 the week before. Meanwhile the producer price index, a
key inflation gauge, rose 0.1 percent in February after a 0.6
percent rise in January.
Stock futures on the Standard & Poor's 500 Index <.SPX>
rose after the data to trade above fair value, indicating a
flat or slightly higher open for the broad index.
"The jobless claims came in better than expected, raising
hopes that tomorrow's employment report will show the
long-awaited job creation," said Phil Flynn, vice president and
senior market analyst at Alaron Trading Corp. "The producer
price index amazingly still shows benign inflation even with
commodity prices seemingly rising all around us."
Investors are worried that inflation will force the Federal
Reserve to raise interest rates before the job market shows
real signs of growth.
The pressure on the Fed to raise rates was kept up by the
European Central Bank on Thursday as it opted to keep its own
interest rates unchanged at 2 percent.
(Additional reporting by Doris Frankel)
(C) Reuters 2004. All rights reserved. Republication or redistribution of
Reuters content, including by caching, framing or similar means, is expressly
prohibited without the prior written consent of Reuters. Reuters and the Reuters
sphere logo are registered trademarks and trademarks of the Reuters group of
companies around the world.
Apr-01-2004 13:48 GMT
Symbols:
US;SPX US;SPL
Source RTRS Reuters News
Categories:
RTI US STX BUS MUNI FIN NEWS DRU ENR LEI RET BEV PKG/USMKT MST/L/EN
MST/R/US MST/S/NDX MST/I/SVC MST/F/MUN MST/I/FIS MST/B/BRK MST/I/DRG MST/I/PIP
MST/I/TMF MST/I/RTB MST/I/BVG
NP! Careful for those April Fools stocks today, lol.
thanks Cap....
Morning all!
Since the stocks covered on this board are more affected by the overall market than the pennies are, I thought I'd offer a heads-up here.
Watch out for volatility caused by major economic news coming out through the end of the week. The PPI and jobless claims numbers moved the futures from negative to positive this morning, and the ISM number is coming out at 10:00 (a big market mover). Also, everyone seems to be holding their breath for the monthly employment report coming out tomorrow morning at 8:30.
OPLK sitting just under the 50EMA. on watch for a cross of that level.
GGNS looking good here. DMI+ cross, and sitting just under the 50EMA.
ECGI set up nicely here. DMI+ crossed upwards today, also Parabolic SAR dropped below the pps, indicating a trend change..And it finished up through the 50EMA. looks good from here. any news coming would be a bonus..
CORV
Don't own it but looks interesting
sorry about these poor charts
new computer should be put togeather sometime tomorrow
can not wait LOL
ECGI looks almost ready to bounce off the intraday 50EMA again here soon...
So, did you ever buy any AAC this morning?
Covered the short; made a big 2.5% on that one lol.
needs to get above .88
ILA: Here's another one I'm missing out on. I've noticed that the MACD method that Omni uses works well, and this signal actually came yesterday. Should have taken it...
BTW, some of the notations I have on these charts may be old. That way I can kind of watch my historical thoughts on it as it moves around.
DFCT: Here's an "island gap" which is supposed to indicate a top or bottom. Not in it, but looks interesting.
Boy, LOOK is chuggin' away today, think we see a pullback here?
AAC..I see your point. Looks like volume at this point would bounce it, no volume and you could expect it to look for the low bolli.
OK, I didn't want to post it until I checked with you first. I will switch from long to short at the drop of a hat if I see the opportunity there; It's just a daytrade on TKO. Here it is:
Sure, shorts are fine too. Don't short much myself, but no problem posting things going up, and things going down..
lol, having the flexibility to go short and to buy puts on indices can double your profit (or loss) potential.
Shorting stocks is Un-American! Oops, that's right - we need to keep the market liquid! lmao (only kidding here, Cap)
That was my understanding as well. Your idea was to be in stocks that have some LIQUIDITY, regardless of whether the symbol has 3 or 4 letters in it.
BTW, what are your thoughts on posting shorts? Just asking because I'm short a stock that just had it's second false breakout and is at the top of a consolidation.
Yeah, that is the idea primarily. Not gonna be super nitpicky about that as long as it's a listed exchange (no OTCBB here)
AAC - good buying opportunity today, but that's AMEX - isn't this supposed to be NAZ stocks?
11/13/2008 – NEW PICS OF FIRST PRODUCTION AT MAGOG FACILITY
Video: http://www.youtube.com/watch?v=HV7AhRdD-1M
http://i372.photobucket.com/albums/oo167/magnumrecyclage/HPIM1153.jpg http://i372.photobucket.com/albums/oo167/magnumrecyclage/HPIM1155.jpg http://i372.photobucket.com/albums/oo167/magnumrecyclage/HPIM1147.jpg http://i372.photobucket.com/albums/oo167/magnumrecyclage/HPIM1154.jpg
Magnum d’Or Resources (MDOR.ob)
Business Description:
In simple terms, Magnum recycles scrap tires into reusable, marketable materials; nuggets, buffings, powders, and crumb rubber each having their respective applications. Magnum has a five year contract with National Sales & Supply(NSS) http://www.nsalessupply.com for $131,000,000 worth of rubber buffings and nuggets for fulfillment of NSS’s contracts with retailers such as Wal-Mart, Lowe’s, Home Depot, and others.
- Production of Rubber Nuggets – http://magnumresources.net/files/rubber-nuggests.ppt
- Production of Rubber Buffings –http://magnumresources.net/files/rubber-buffings.ppt
- Production of TPE’s - http://magnumresources.net/files/elastomeric-alloys.ppt
Magnum recently announced a new research & development program, long term partnership, and joint venture with Sekhar Research Innovations Sdn Bhd (SRI) http://srielastomers.com Magnum will receive immediate exclusivity for North America and future global rights to an array of next generation cost saving custom compounds targeted at a wide spectrum of applications. In addition, Magnum will have access to state of the art processing aids and new world proprietary rubber recycling equipment.
Contact Info:
Magnum D’Or Resources Inc.
1326 SE 17th St. Suite 513
Ft. Lauderdale, FL 33316
PH: 305-420-6563
FAX: 305-395-4858
http://www.magnumresources.net
Share Structure: (11/11/2008)
Authorized: 200,000,000
Preferred: (voting, non-convertible): 10,000,000
Common Outstanding: 22,416,637
Common Float: 8,914,043
Transfer Agent:
Holladay Stock Transfer, Inc.
2939 N 67th Pl Ste C
Scottsdale, AZ 85251
(480) 481-3940
Corporate Domicile:
Nevada Secretary of State Record
Press Releases:
http://www.magnumresources.net/news.php
SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099963&owner=include&count=40
Internal Controls:
Magnum is a reporting company, and their accountant, Weinberg & Company, P.A. is one of the best in the business http://www.cpaweinberg.com/news.pdf Also, Magnum has recently retained Canadian consulting firm Raymond Chabot Grant Thornton http://www.rcgt.com/Aboutus.aspx?NavID=117&CultureCode=en to assist with internal controls and revenue projections.
Pictures of Various MDOR facilities:
http://www.magnumresources.net/investors.php
Audio Interview:
10/13/2008 TradersNation interview with Chad Curtis
http://www.tradersnation.com/player/?id=414
Chart:
The rising “Money Flow” and “On Balance Volume” indicate a great amount of accumulation has been, and is still going on.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |